公开(公告)号：US20090186368A1

公开(公告)日：2009-07-23

申请号：US12285766

申请日：2008-10-14

申请人： Neil David Hammond Raven ,  Matthew Patrick Wictome ,  J. Mark Sutton ,  Susan O'Brien ,  Heather Murdoch

发明人： Neil David Hammond Raven ,  Matthew Patrick Wictome ,  J. Mark Sutton ,  Susan O'Brien ,  Heather Murdoch

IPC分类号： G01N33/53

CPC分类号： G01N33/581 ,  C12Q1/485 ,  C12Q1/66 ,  Y10T436/25125

摘要： In an assay, an analyte in a sample is contacted with a thermostable reporter adenylate kinase coupled to a binding agent specific for the analyte, wherein a complex is formed. ADP is added, and then formation of ATP is monitored. Prior to the addition of ADP, endogenous kinase and uncomplexed thermostable reporter adenylate kinase is substantially removed by washing and residual endogenous kinase is inactivated by heating. Prior to contacting the analyte with the thermostable reporter adenylate kinase, the sample has a background activity of at least 300,000 Relative Light Units per mg protein per ml sample when measured in the presence of luciferin/luciferase by a luminometer.

摘要翻译： 在测定中，将样品中的分析物与偶联到分析物特异性结合剂的热稳定报告基因腺苷酸激酶接触，其中形成复合物。 添加ADP，然后监测ATP的形成。 在添加ADP之前，通过洗涤基本上除去内源性激酶和未复合的热稳定报告基因腺苷酸激酶，并且通过加热使残留的内源性激酶失活。 在将分析物与热稳定报告基因腺苷酸激酶接触之前，当在荧光素/荧光素酶存在下通过发光计测量时，样品的背景活性为每毫升样品中每mg蛋白质至少300,000个相对光单位。

公开(公告)号：US20050208608A1

公开(公告)日：2005-09-22

申请号：US11065700

申请日：2005-02-25

申请人： Neil David Raven ,  Matthew Wictome ,  J. Sutton ,  Susan O'Brien ,  Heather Murdoch

发明人： Neil David Raven ,  Matthew Wictome ,  J. Sutton ,  Susan O'Brien ,  Heather Murdoch

IPC分类号： G01N33/543 ,  C12Q1/34 ,  C12Q1/48 ,  C12Q1/66 ,  G01N33/58

CPC分类号： G01N33/581 ,  C12Q1/485 ,  C12Q1/66 ,  Y10T436/25125

摘要： In an assay, an analyte in a sample is contacted with a thermostable reporter adenylate kinase coupled to a binding agent specific for the analyte, wherein a complex is formed. ADP is added, and then formation of ATP is monitored. Prior to the addition of ADP, endogenous kinase and uncomplexed thermostable reporter adenylate kinase is substantially removed by washing and residual-endogenous kinase is inactivated by heating. Prior to contacting the analyte with the thermostable reporter adenylate kinase, the sample has a background activity of at least 300,000 Relative Light Units per mg protein per ml sample when measured in the presence of luciferin/luciferase by a luminometer.

摘要翻译： 在测定中，将样品中的分析物与偶联到分析物特异性结合剂的热稳定报告基因腺苷酸激酶接触，其中形成复合物。 添加ADP，然后监测ATP的形成。 在添加ADP之前，通过洗涤基本上除去内源性激酶和未复合的热稳定报告基因腺苷酸激酶，并且通过加热使残留的内源性激酶失活。 在将分析物与热稳定报告基因腺苷酸激酶接触之前，当在荧光素/荧光素酶存在下通过发光计测量时，样品的背景活性为每毫升样品中每mg蛋白质至少300,000个相对光单位。

公开(公告)号：US20080051400A1

公开(公告)日：2008-02-28

申请号：US11825194

申请日：2007-07-05

申请人： Jean Viallet ,  Susan O'Brien

发明人： Jean Viallet ,  Susan O'Brien

IPC分类号： A61K31/4025 ,  A61K31/497 ,  A61K31/5377 ,  A61P7/02 ,  A61P7/06

CPC分类号： A61K31/4025 ,  A61K31/497 ,  A61K31/5377

摘要： The present invention relates to methods useful for treating or preventing anemia or thrombocytopenia, comprising administrating an effective amount of a Triheterocyclic Compound to a subject in need thereof. The present invention also relates to methods useful for preventing anemia or thrombocytopenia in a subject, comprising administrating an effective amount of a Triheterocyclic Compound to the subject, wherein the subject is at heightened risk of developing anemia or thrombocytopenia.

摘要翻译： 本发明涉及可用于治疗或预防贫血或血小板减少症的方法，包括向有需要的受试者施用有效量的三环杂环化合物。 本发明还涉及可用于预防受试者的贫血或血小板减少症的方法，其包括向所述受试者施用有效量的三元杂环化合物，其中所述受试者处于发展贫血或血小板减少症的高度风险中。

公开(公告)号：US20060287240A1

公开(公告)日：2006-12-21

申请号：US11508033

申请日：2006-08-21

申请人： John O'Brien ,  D. Parks ,  Susan O'Brien

发明人： John O'Brien ,  D. Parks ,  Susan O'Brien

IPC分类号： A61K38/10

CPC分类号： A61K38/18 ,  A61K48/00 ,  C07K1/14 ,  Y02A50/466

摘要： A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed by reintroduction of the cells into an individual.

公开(公告)号：US07455657B2

公开(公告)日：2008-11-25

申请号：US09883178

申请日：2001-06-19

申请人： Wendy Naimark ,  Susan O'Brien ,  Brandon Shuman

发明人： Wendy Naimark ,  Susan O'Brien ,  Brandon Shuman

IPC分类号： A61M37/00 ,  A61M25/00

CPC分类号： A61M25/003 ,  A61M5/142 ,  A61M5/1582 ,  A61M25/0071 ,  A61M2025/0004 ,  A61M2025/0031 ,  A61M2025/0039 ,  A61M2025/0057 ,  A61M2205/75 ,  B01D61/14 ,  B01D61/18 ,  B01D63/06

摘要： Method and apparatus to modify a fluid by passing a compound through a selectively permeable membrane is provided. In one embodiment a fluid moving through a vessel is modified prior to its ejection from the vessel. This may be accomplished by urging the fluid into a mixing chamber wherein the mixing chamber is in fluid communication with an exit orifice and a passageway. This passageway may be in communication with a second chamber through a selectively permeable membrane. The fluid may then be altered by passing a compound between the mixing chamber and the second chamber through the passageway and the selectively permeable membrane. A device for modifying a fluid moving through a vessel may contain a first lumen, a second lumen, an exit orifice, and a mixing chamber in communication with the first lumen and the exit orifice.

摘要翻译： 提供了通过使化合物通过选择性渗透膜来改变流体的方法和装置。 在一个实施例中，移动通过容器的流体在其从容器中排出之前被改变。 这可以通过将流体推入混合室来实现，其中混合室与出口孔和通道流体连通。 该通道可以通过选择性渗透膜与第二室连通。 然后可以通过使混合室和第二室之间的化合物通过通道和选择性渗透膜来改变流体。 用于改变流过血管的流体的装置可以包含与第一腔和出口连通的第一腔，第二腔，出口孔和混合室。